8-K: Mallinckrodt and Endo Shareholders Greenlight Combination to Form Global Pharma Leader

Shareholders of Mallinckrodt plc and Endo, Inc. have overwhelmingly approved the proposed stock and cash transaction, clearing a major hurdle for the creation of a global, diversified pharmaceuticals leader.

Summary

• Endo, Inc. convened a special meeting of stockholders on June 13, 2025, with 81.09% of outstanding shares (61,881,572 out of 76,313,462) present or represented by proxy, constituting a quorum.
• Proposal 1, the Transaction Proposal, which includes the merger of Merger Sub into Endo making Endo a wholly owned subsidiary of Mallinckrodt and leading to Endo's delisting and deregistration, was approved with 61,792,120 votes For, 89,452 Against, and 0 Abstentions.
• Proposal 2, the non-binding advisory Distributable Reserves Proposal for Mallinckrodt's share premium account reduction, was approved with 61,792,120 votes For, 89,452 Against, and 0 Abstentions.
• Proposal 3, the non-binding advisory Combination-Related Compensation Proposal for executive compensation, was approved with 61,772,299 votes For, 108,528 Against, and 745 Abstentions.
• All eight sub-proposals under Proposal 4, the Mallinckrodt Articles Amendment Proposals, were approved, which relate to Mallinckrodt's share capital, shareholder rights, quorum, voting procedures, board size, director appointments, and alignment with customary U.S. listed company practices for a potential NYSE listing.
• Mallinckrodt will now apply to the Irish High Court to confirm the scheme of arrangement, with the companies targeting completion of the merger in the weeks following a potential July sanction hearing.
• Post-merger, the combined company's global headquarters will be in Dublin, Ireland, and there are plans to combine their generic pharmaceuticals businesses and Endo's sterile injectables business, with a future separation of this combined business.
• Endo's common stock will be delisted from the OTCQX Best Market and deregistered under the Securities Exchange Act of 1934 as a result of the business combination.

Sentiment

Score: 8

Explanation: The overwhelming shareholder approval for all proposals indicates strong support for the merger, which is a critical step towards its completion. Management expresses confidence in value creation and strategic positioning. However, the document also lists extensive forward-looking risks inherent in such large-scale combinations and integrations, warranting a slightly tempered positive score.

Positives

• Shareholders of both Mallinckrodt and Endo have provided the necessary approvals for the combination, marking a significant step towards closing the transaction.
• The combination is expected to create a 'global, scaled, diversified pharmaceuticals leader,' enhancing market position and capabilities.
• Management anticipates accelerated value creation for shareholders, customers, and employees, ultimately benefiting patients.
• The merger is positioned to deliver improved product portfolios to patients and drive sustainable long-term value for shareholders and stakeholders.
• The planned separation of the combined generics and sterile injectables businesses post-merger could unlock further strategic value and focus.

Negatives

• Endo, Inc. will cease to be a publicly held company, with its common stock being delisted from the OTCQX Best Market and deregistered.
• The transaction involves significant integration risks, including unanticipated costs and the possibility that the combined company may not operate as effectively or efficiently as expected.
• There is inherent uncertainty regarding the exact timing of the Irish High Court hearing and its decision to approve the scheme of arrangement.
• The proposed business combination will result in increased indebtedness for Mallinckrodt.
• The transaction is associated with significant transaction costs.

Risks

• Inability to successfully integrate Mallinckrodt's and Endo's businesses and unanticipated costs of such integration, potentially leading to the combined company not operating as effectively and efficiently as expected.
• Uncertainties related to a future separation of the combined generics pharmaceuticals businesses of Mallinckrodt and Endo and Endo's sterile injectables business.
• The risk that the expected benefits and synergies of the proposed transactions may not be fully realized in a timely manner, or at all.
• Uncertainty regarding the timing of the closing of the proposed business combination transaction.
• The risk that the conditions to the proposed business combination transaction may not be satisfied (or waived to the extent permitted by law) on a timely basis or at all, or the failure of the proposed business combination transaction to close for any other reason or to close on the anticipated terms, including the intended tax treatment.
• The occurrence of any event, change or other circumstance that could give rise to the termination of the proposed business combination transaction.
• Unanticipated difficulties, liabilities or expenditures relating to the proposed transactions.
• The effect of the announcement, pendency or completion of the proposed transactions on the parties' business relationships and business operations generally.
• Certain restrictions on the ability of Mallinckrodt and Endo to pursue certain business activities or strategic transactions during the pendency of the proposed business combination transaction.
• The effect of the announcement, pendency or completion of the proposed transactions on the long-term value of Mallinckrodt's ordinary shares and Endo's common stock.
• Risks that the proposed transactions may disrupt current plans and operations of Mallinckrodt and Endo and their respective management teams and potential difficulties in hiring, retaining and motivating employees as a result of the proposed transactions.
• Risks related to increased indebtedness as a result of the proposed business combination transaction.
• Significant transaction costs related to the proposed business combination transaction.
• Potential litigation relating to the proposed transactions that could be instituted against Mallinckrodt, Endo or their respective officers or directors.
• Rating agency actions and Mallinckrodt's and Endo's ability to access shortand long-term debt markets on a timely and affordable basis.
• Risks related to the financing in connection with the transaction.
• Governmental investigations and inquiries, regulatory actions, and lawsuits related to Mallinckrodt or its officers.
• Mallinckrodt's contractual and court-ordered compliance obligations that, if violated, could result in penalties.
• Compliance with and restrictions under the global settlement to resolve all opioid-related claims.
• Matters related to Acthar Gel, including the settlement with governmental parties to resolve certain disputes and compliance with and restrictions under the related corporate integrity agreement.
• The ability to maintain relationships with Mallinckrodt's suppliers, customers, employees and other third parties following the emergence from the 2023 bankruptcy proceedings.
• Scrutiny from governments, legislative bodies and enforcement agencies related to sales, marketing and pricing practices.
• Pricing pressure on certain of Mallinckrodt's products due to legal changes or changes in insurers or other payers' reimbursement practices.
• The reimbursement practices of governmental health administration authorities, private health coverage insurers and other third-party payers.
• Complex reporting and payment obligations under the Medicare and Medicaid rebate programs and other governmental purchasing and rebate programs.
• Cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations.
• Changes in or failure to comply with relevant laws and regulations.
• Any undesirable side effects caused by Mallinckrodt's approved and investigational products, which could limit their commercial profile or result in other negative consequences.
• Mallinckrodt's and its partners' ability to successfully develop, commercialize or launch new products or expand commercial opportunities of existing products.
• Mallinckrodt's ability to successfully identify or discover additional products or product candidates.
• Mallinckrodt's ability to navigate price fluctuations and pressures, including the ability to achieve anticipated benefits of price increases of its products.
• Competition in the pharmaceutical market.
• Mallinckrodt's ability to protect intellectual property rights, including in relation to ongoing and future litigation.
• Limited clinical trial data for Acthar Gel.
• The timing, expense and uncertainty associated with clinical studies and related regulatory processes.
• Product liability losses and other litigation liability.
• Material health, safety and environmental laws and related liabilities.
• Business development activities or other strategic transactions.
• Attraction and retention of key personnel.
• The effectiveness of information technology infrastructure, including risks of external attacks or failures.
• Customer concentration.
• Mallinckrodt's reliance on certain individual products that are material to its financial performance.
• Mallinckrodt's ability to receive sufficient procurement and production quotas granted by the U.S. Drug Enforcement Administration.
• Complex manufacturing processes.
• Reliance on third-party manufacturers and supply chain providers and related market disruptions.
• Conducting business internationally.
• Mallinckrodt's significant levels of intangible assets and related impairment testing.
• Natural disasters or other catastrophic events.
• Mallinckrodt's substantial indebtedness and settlement obligation, its ability to generate sufficient cash to reduce its indebtedness and its potential need and ability to incur further indebtedness.
• Restrictions contained in the agreements governing Mallinckrodt's indebtedness and settlement obligation on Mallinckrodt's operations, future financings and use of proceeds.
• Mallinckrodt's variable rate indebtedness.
• Mallinckrodt's tax treatment by the Internal Revenue Service under Section 7874 and Section 382 of the Internal Revenue Code of 1986, as amended.
• Future changes to applicable tax laws or the impact of disputes with governmental tax authorities.
• The impact of Irish laws.
• The impact on the holders of Mallinckrodt's ordinary shares if Mallinckrodt were to cease to be a reporting company in the United States.
• The comparability of Mallinckrodt's post-emergence financial results and the projections filed with the Bankruptcy Court.
• The lack of comparability of Mallinckrodt's historical financial statements and information contained in its financial statements after the adoption of fresh-start accounting following emergence from the 2023 bankruptcy proceedings.
• Future capital expenditures, expenses, revenues, economic performance, financial conditions, market growth and future prospects for Endo's business.
• Changes in competitive, market or regulatory conditions affecting Endo.
• Changes in legislation or regulations impacting Endo.
• Global political changes, including those related to the new U.S. presidential administration, affecting Endo.
• Endo's use of artificial intelligence and data science.
• The ability to obtain and maintain adequate protection for intellectual property rights for Endo's products.
• The impacts of competition such as those related to XIAFLEX.
• The timing and uncertainty of the results of both the research and development and regulatory processes for Endo's products.
• Health care and cost containment reforms, including government pricing, tax and reimbursement policies.
• The performance including the approval, introduction and consumer and physician acceptance of current and new products for Endo.
• The performance of third parties upon whom Endo relies for goods and services.
• Issues associated with Endo's supply chain.
• Endo's ability to develop and expand its product pipeline and to launch new products and to continue to develop the market for XIAFLEX and other branded, sterile injectable or generic products.
• The effectiveness of advertising and other promotional campaigns for Endo's products.
• The timely and successful implementation of business development opportunities and/or any other strategic priorities for Endo.

Future Outlook

The companies aim to create a global, scaled, diversified pharmaceuticals leader. They plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after the close of the transaction, with a future separation of that combined business. Mallinckrodt will apply to the Irish High Court for approval of the scheme of arrangement, targeting completion of the merger in the weeks following a potential July sanction hearing. The Mallinckrodt Articles Amendment Proposals also suggest a potential future listing of Mallinckrodt's shares on the New York Stock Exchange.

Management Comments

• Siggi Olafsson, President and Chief Executive Officer of Mallinckrodt (and future CEO of the combined company), stated: "We are pleased that our respective shareholders recognize the opportunity in combining these two essential pharmaceuticals organizations to accelerate value creation for our shareholders, customers, and employees, for the ultimate benefit of the patients we serve."
• Scott Hirsch, Interim CEO of Endo, commented: "This milestone marks an important step forward in the combination of two highly complementary companies. As we move toward the merger and planned separation of the sterile injectables and generics businesses, we are positioning to deliver improved product portfolios to patients and drive sustainable long-term value for our shareholders and stakeholders."

Industry Context

This transaction represents a significant consolidation within the pharmaceutical sector, aiming to create a larger, more diversified entity. The strategic decision to combine and then potentially separate the generics and sterile injectables businesses aligns with broader industry trends where companies often streamline operations to focus on higher-margin specialty areas or to unlock value through focused business units. The establishment of the combined company's global headquarters in Dublin, Ireland, also reflects common international corporate structuring strategies in the pharmaceutical industry.

Management Changes

Corporate Governance

Legal Proceedings

• The document mentions risks of "potential litigation relating to the proposed transactions that could be instituted against Mallinckrodt, Endo or their respective officers or directors."
• Mallinckrodt's business risks include "governmental investigations and inquiries, regulatory actions, and lawsuits, in each case related to Mallinckrodt or its officers."
• Mallinckrodt also faces risks related to "contractual and court-ordered compliance obligations that, if violated, could result in penalties," and "compliance with and restrictions under the global settlement to resolve all opioid-related claims."
• Specific mention is made of "matters related to Acthar Gel, including the settlement with governmental parties to resolve certain disputes and compliance with and restrictions under the related corporate integrity agreement."
• Endo's business risks include general "litigation."

Related Party Transactions

• Proposal 3, the "Combination-Related Compensation Proposal," sought non-binding advisory approval for compensation that will or may become payable by Endo or its subsidiaries to its named executive officers in connection with the consummation of the Transaction.

Stakeholder Impact

• **Endo Shareholders**: Will no longer hold publicly traded shares of Endo, as Endo will become a wholly owned subsidiary of Mallinckrodt, leading to delisting and deregistration. They will become shareholders of Mallinckrodt.
• **Mallinckrodt Shareholders**: Will be part of a larger, diversified company, with management anticipating accelerated value creation.
• **Customers**: Expected to benefit from "improved product portfolios" resulting from the combination.
• **Employees**: Management states the combination will accelerate value creation for employees. However, the document also notes risks of potential disruption to current plans and operations and difficulties in hiring, retaining, and motivating employees as a result of the proposed transactions.
• **Patients**: Expected to benefit from "improved product portfolios."

Next Steps

• Mallinckrodt will apply to the Irish High Court to confirm the scheme of arrangement.
• Mallinckrodt and Endo are targeting completing the merger in the weeks following the sanction hearing (expected July).
• Post-merger close, the combined company plans to combine their generic pharmaceuticals businesses and Endo's sterile injectables business.
• A future separation of the combined generics and sterile injectables business is planned, subject to approval by the combined company's Board of Directors and other conditions.
• Mallinckrodt's articles of association have been amended in a form customary for a potential listing of Mallinckrodt's shares on the New York Stock Exchange.

Key Dates

Recommendation

Keywords

Mallinckrodt, Endo, Merger, Acquisition, Pharmaceuticals, Generics, Sterile Injectables, Healthcare, SEC Filing, 8-K, Shareholder Vote, Business Combination, Corporate Governance, Delisting, Deregistration